Video Highlights
1:18 Kimberly Green, PhD
2:22 S. Wilson Beckham, PhD, MPH, MA
3:44 Renee Heffron, PhD, MPH
4:28 Laura Rusie, ScM
|Videos|August 22, 2021
The Potential Addition of Long-Acting Injectables for PrEP
Author(s)John Parkinson
What does this form of pre-exposure prophylaxis (PrEP) mean in terms of options and initiation.
Advertisement
Welcome to our series, 1 Big Question, which asks 1 question to the medical community and we get their feedback on an important infectious disease topic.
In this episode, our 1 Big Question is: Do you think the addition of long-term acting injectables for PrEP will lead to greater utilization of it?
We interviewed Kimberly Green, PhD, global program director, Primary Health Care, PATH; S. Wilson Beckham, PhD, MPH, MA, assistant scientist, Department of Health, Behavior and Society, and Department of International Health—Social & Behavioral Sciences, Johns Hopkins Bloomberg School of Public Health; Renee Heffron, PhD, MPH, associate professor, Global Health, associate professor, Epidemiology, Department of Global Health, University of Washington; and Laura Rusie, ScM director of Data, Evaluation, and Epidemiology, Howard Brown Health.
Watch the video to hear their insights.
Advertisement
Related to this article
Long-acting cabotegravir plus rilpivirine (Cabenuva) achieved superior viral suppression vs daily oral antiretroviral therapy at 6months in treatment-experienced people with HIV and detectable viremia in the phase 3b CROWN trial.
Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
New gyrA testing guides ciprofloxacin use for gonorrhea, cutting ceftriaxone reliance while tackling resistance, access, and FDA hurdles.
Demonstrating a diagnostic test works is no longer enough. Clinicians and laboratories also need evidence on how to adopt it in everyday practice. Andrea Prinzi, PhD, MPH, SM(ASCP), explains how implementation science can help infectious disease and clinical microbiology teams turn evidence into routine care.
Kenya reported its first imported Bundibugyo Ebola death as the Democratic Republic of Congo (DRC) outbreak surpassed 8,600 confirmed cases and 4,148 deaths, with 896 patients hospitalized in isolation. Here is a report on the latest numbers as well as vaccine and therapeutic study updates.